BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38433382)

  • 21. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
    Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
    Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
    Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritumoral D2-40 Chalkley score independently predicts metastases and survival in patients with cutaneous malignant melanoma.
    Pastushenko I; Vermeulen PB; Vicente-Arregui S; Van den Eynden GG; Alvarez-Alegret R; Querol I; Rutten A; Carapeto FJ; Dirix LY; Van Laere S
    J Cutan Pathol; 2015 Oct; 42(10):699-711. PubMed ID: 26264662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple combinations of melanocytic and vascular endothelial markers enhance the detection rate of lymphovascular invasion in cutaneous melanoma.
    Bayram A; Ozturk Sari S; Ozluk Y; Tas F; Buyukbabani N
    J Cutan Pathol; 2021 Apr; 48(4):472-478. PubMed ID: 32935876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
    Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
    Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histological regression in melanoma: impact on sentinel lymph node status and survival.
    Aivazian K; Ahmed T; El Sharouni MA; Stretch JR; Saw RPM; Spillane AJ; Shannon KF; Ch'ng S; Nieweg OE; Thompson JF; Lo SN; Scolyer RA
    Mod Pathol; 2021 Nov; 34(11):1999-2008. PubMed ID: 34247192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer.
    Grabowski JP; Glajzer J; Richter R; Plett H; Muallem MZ; Braicu EI; Taube E; Sehouli J
    Int J Gynecol Cancer; 2021 Jan; 31(1):98-103. PubMed ID: 33127866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sentinel lymph node biopsy for melanoma: experience with 234 consecutive procedures.
    Wagner JD; Corbett L; Park HM; Davidson D; Coleman JJ; Havlik RJ; Hayes JT
    Plast Reconstr Surg; 2000 May; 105(6):1956-66. PubMed ID: 10839392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma.
    Kyrgidis A; Tzellos T; Mocellin S; Apalla Z; Lallas A; Pilati P; Stratigos A
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD010307. PubMed ID: 25978975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of Ki-67 and Estrogen Receptor Beta in Primary Cutaneous Melanoma as a Potential Indicator of Regional Lymph Node Positivity.
    Udovicic-Gagula D; Ahmovic A; Bilalovic N; Doric M
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):27-32. PubMed ID: 28549035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.
    Sun W; Xu Y; Yang J; Liao Z; Li T; Huang K; Patel P; Yan W; Chen Y
    Cancer Commun (Lond); 2020 Nov; 40(11):586-597. PubMed ID: 33025763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes.
    Dadras SS; Lange-Asschenfeldt B; Velasco P; Nguyen L; Vora A; Muzikansky A; Jahnke K; Hauschild A; Hirakawa S; Mihm MC; Detmar M
    Mod Pathol; 2005 Sep; 18(9):1232-42. PubMed ID: 15803182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study.
    Shannon AB; Sharon CE; Straker RJ; Carr MJ; Sinnamon AJ; Bogatch K; Thaler A; Kelly N; Vetto JT; Fowler G; DePalo D; Sondak VK; Miura JT; Faries MB; Bartlett EK; Zager JS; Karakousis GC
    J Am Acad Dermatol; 2023 Jan; 88(1):52-59. PubMed ID: 36184008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time to Procedure, Nuclear Imaging and Clinicopathological Characteristics as Predictive Factors for Sentinel Lymph Node Metastasis in Cutaneous Melanoma: A Single-Center Analysis.
    Jaukovic L; Rajović M; Kandolf Sekulovic L; Radulovic M; Stepic N; Mijuskovic Z; Petrov N; Ajdinovic B
    Ann Plast Surg; 2018 Jul; 81(1):80-86. PubMed ID: 29762449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up.
    Leong SP; Kashani-Sabet M; Desmond RA; Kim RP; Nguyen DH; Iwanaga K; Treseler PA; Allen RE; Morita ET; Zhang Y; Sagebiel RW; Soong SJ
    World J Surg; 2005 Jun; 29(6):683-91. PubMed ID: 15895193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple-marker PCR assay of sentinel lymph node as a prognostic factor in melanoma.
    Ito T; Wada M; Nagae K; Nakano-Nakamura M; Nakahara T; Hagihara A; Furue M; Uchi H
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):912-8. PubMed ID: 25199412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ki-67 expression in melanoma. A potential method of risk assessment for the patient with a positive sentinel node.
    Pearl RA; Pacifico MD; Richman PI; Stott DJ; Wilson GD; Grobbelaar AO
    J Exp Clin Cancer Res; 2007 Mar; 26(1):109-15. PubMed ID: 17550139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.